Duodenal Mucosal Resurfacing: A Potential Solution for Weight Maintenance After GLP-1 Discontinuation

A preliminary study suggests a minimally invasive endoscopic procedure may help patients maintain weight loss after stopping GLP-1 receptor agonist therapy.

Study Overview

A midpoint analysis of the REMAIN-1 trial, presented at Digestive Disease Week (DDW)2026, explored whether duodenal mucosal resurfacing (DMR) could help sustain weight loss after discontinuing tirzepatide, a GLP-1 medication. The trial, sponsored by Fractyl Health, is a blinded, randomized, sham-controlled study.

Participants

The midpoint cohort included 45 participants, all of whom had lost at least 15% of their total body weight while on tirzepatide before stopping the drug:

• 29 participants received the DMR procedure
• 16 participants received a sham procedure

The full REMAIN-1 trial is fully enrolled with over 300 participants.

Key Findings

Participants lost an average of approximately 40 pounds while on tirzepatide therapy. Six months after discontinuing the drug and undergoing their assigned procedure, researchers observed notable differences:

The sham control group regained approximately 40% more weight than the DMR treatment group.

• Participants who received more extensive duodenal tissue resurfacing regained an average of about 7 pounds, maintaining over 80% of their weight loss.
• The sham control group regained approximately double the weight (about 14 pounds) compared to the group with more extensive resurfacing.

The difference in weight regain between the DMR and sham groups appeared to widen between one and six months post-intervention, suggesting a sustained benefit over time.

For context, sources note that approximately 70% of individuals who stop GLP-1 medications typically regain significant weight within 18 months.

Safety and Recovery

Investigators reported no serious complications from the DMR procedure. Recovery time was described as approximately one day, with minimal post-procedure symptoms.

How the Procedure Works

Duodenal mucosal resurfacing is a minimally invasive endoscopic procedure that uses controlled heat to ablate damaged tissue in the duodenal mucosal layer. According to researchers, this layer can thicken due to high-fat, high-sugar diets, potentially affecting hormone production and metabolism. The procedure aims to promote regrowth of healthier tissue and reset metabolic responses.

Limitations and Next Steps

Lead author Shelby Sullivan, MD, stated that the procedure may offer a minimally invasive option for weight maintenance after GLP-1 discontinuation. However, the reported findings are preliminary and based on a subgroup of the trial.

Topline six-month data from the full pivotal cohort of the REMAIN-1 trial are expected in early fourth quarter of 2026.

A planned marketing submission to regulatory authorities is anticipated later that year.